Parnax Lab Ltd

Dematerialisation status

• No dematerialisation requests were received during the quarter.
• Securities dematerialised have been listed on the relevant stock exchanges.
• Physical certificates for dematerialisation were mutilated and cancelled after verification; depository name substituted as registered owner within timelines.

AGM Details

• AGM held on 29 September 2026 at 12:30 PM via VC/OAVM.
• Remote e-voting from 26 to 28 September 2026.

Key Resolutions

• Resolution 1: Adoption of standalone and consolidated financial statements.
• Resolution 2: Re-appointment of Mihir M. Shah as director by rotation.
• Resolution 3: Appointment of Ladha Singhal & Associates as Statutory Auditors for five-year term.
• Resolution 4: Approval of related party transactions with Naxpar Pharma Private Limited.
• Note: Promoter group abstained from voting on RPT.

Voting Results

• Resolution 1 passed with 100% in favour.
• Resolution 2 passed with 100% in favour.
• Resolution 3 passed with 100% in favour.
• Resolution 4 passed; promoter group abstained; all votes cast in favour.

Dividend

• No dividend proposed or declared.

Director Changes

• Mihir M. Shah re-appointed as director by rotation.

Auditor Appointments

• Statutory auditors appointed for first term of 5 years.

Material Related Party Transactions

• Counterparty: Naxpar Pharma Private Limited; nature: related party transactions; value not disclosed.

AGM details

• AGM held on Sep 29, 2026 at 12:30 PM IST via VC/OAVM.
• Meeting concluded at 1:07 PM IST; e-voting period Sep 26–28, 2026.

Key resolutions

• Ordinary: adopt standalone and consolidated financial statements for year ended Mar 31, 2026.
• Ordinary: re-appointment of Mihir Shah, retiring by rotation.
• Special: appoint Ladha Singhal & Associates as Statutory Auditor for 5-year term.
• Ordinary: approve material related party transactions with Naxpar Pharma Private Limited.

Voting results

• All resolutions passed with requisite majority.
• Detailed results to be posted separately on the company website.

Director changes

• Director Mihir Shah re-appointed as director (retiring by rotation).

Auditor appointments

• Ladha Singhal & Associates appointed as Statutory Auditor for 5 years.

Material related party transactions

• Material RPT approved with Naxpar Pharma Private Limited.

Parnax Lab Ltd — Trading Window closed from 01 October 2026; The Trading Window shall open 48 hours after the Unaudited Financial Result for the Quarter and Half Year ended 30t September, 2026, becomes generally available to the public.

AGM details

• AGM date/time/mode: 29 September 2026 at 12:30 PM via VC/OAVM.
• Members register closure: 23-29 September 2026.

Resolutions proposed

• Ordinary: Adoption of standalone and consolidated accounts and reports.
• Ordinary: Re-appointment of Mihir M. Shah (retires by rotation).
• Ordinary: Appointment of Ladha Singhal & Associates as Statutory Auditor for five years.
• Special: Approval of Material Related Party Transactions with Naxpar Pharma Private Limited for FY2026-27 and FY2027-28.

Auditor appointment

• Statutory Auditor appointed: Ladha Singhal & Associates for first term of five years.

Related party transactions

• Transactions with Naxpar Pharma Private Limited: sale and purchase of materials; interest income.
• Per-transaction value cap: up to Rs 5 crore; aggregate FY2026-27 up to Rs 5 crore per transaction.
• Interest up to Rs 1.5 crore; duration 01 Oct 2026 to 30 Sep 2027; 15 months.

Director changes

• Mihir Shah to be re-appointed as director (retiring by rotation).

Other notes

• AGM to be conducted through VC/OAVM; no physical attendance.

Financials

• Standalone revenue from operations: 662.51 Lakhs, down YoY from 701.90.
• Standalone PAT: 88.75 Lakhs; prior year 139.46.
• Standalone EPS: 0.77 Rs.
• Consolidated revenue from operations: 24854.43 Lakhs; up from 18,773.78.
• Consolidated PAT: 1179.86 Lakhs.
• Consolidated EPS: 10.27 Rs.
• Dividend declared: Nil.
• AGM scheduled for 29 September 2026 via VC/OAVM.

Operations & Segment

• Segment: single Pharmaceuticals trading; no separate segment reporting.

Capital & Dividends

• Paid-up share capital remains Rs 1,148.56 Lakhs.
• Authorized capital Rs 1,300.00 Lakhs.
• Dividend policy notes indicate no dividend for 2025-26.

Related Party Transactions

• RPTs with subsidiary Naxpar Pharma approved up to Rs 5 Crore per transaction.
• Interest receipts from subsidiary capped at Rs 1.5 Crores per year.
• Policy on RPTs updated; approvals by Audit Committee and Board.

Governance & Auditors

• Independent Director Yogesh Varia reappointed for second term (2026-2031).
• Statutory Auditor: Ladha Singhal & Associates appointed for 5 years (2026-2030).
• Board comprises six directors: 2 executive, 1 woman non-exec, 3 independent.

Subsidiary & Compliance

• Naxpar Pharma Private Limited is a material subsidiary.
• Subsidiary holds 99.80% shareholding.

Risks & Outlook

• Outlook positive for pharma growth; geographic expansion planned.
• Risks include non-profitable operations and regulatory changes.
• Labour Code impact recognised as exceptional item in standalone Rs 136.93 Lakhs.

Internal Controls & Governance

• Internal financial controls exist; no material weaknesses per Audit Committee.
• Secretarial audit by HSPN & Associates LLP; compliance certificate issued.

Standalone results

• Board approved standalone unaudited results for the quarter ended 30 June 2026.
• Single segment: Dealing in Pharmaceutical Formulations; AS 17 not applicable.
• AGM scheduled for September 29, 2026 via VC/OVAM.
• In-principle appointment of M/s Ladha Singhal & Associates as Statutory Auditors till 2031, subject to shareholders' approval.
• Labour Code impact disclosed as Exceptional Items; standalone Rs 3.49 Lakhs for year ended 31 Mar 2026.

Consolidated results

• Consolidated unaudited results include holding company and subsidiary.
• Labour Code impact on consolidated results: Rs 136.93 Lakhs for year ended 31 Mar 2026 under Exceptional Items.
• Limited Review of consolidated results conducted by Statutory Auditors.
• Consolidated results approved by Board; Limited Review completed.
• There are no outstanding defaults on loans and debt securities.

Governance & other notes

• Board meeting held on August 11, 2026; results reviewed by Audit Committee.
• Company operates in one segment: Dealing in Pharmaceutical Formulations.

Transaction details and impact

• Purpose: Exemption under Regulation 10(1)(a)(ii) for inter-se transfer by gift within promoter group.
• Date and parties: transfer on July 20, 2026 from Ila B. Shah to Prakash Shah.
• Shares transferred: 3,61,872 shares.
• Consideration: gift; no monetary consideration.
• Acquirer pre-transaction: 12,01,676 shares (10.46%).
• Acquirer post-transaction: 15,63,548 shares (13.61%).
• Seller pre-transaction: 13,61,872 shares (11.86%).
• Seller post-transaction: 10,00,000 shares (8.71%).
• Total promoter group holding remains 25,63,548 shares (22.32%).
• Promoter group status unchanged; no change in control.
• Filed within 21 working days; fees paid; Annexures attached.
• 10(5) disclosure to stock exchanges filed (June 25, 2026).
• 10(6) disclosure filed (July 24, 2026).
• Acquirer confirms compliance with 10(1)(a)(ii) exemptions.
• Special context: Gift within promoter group; not an open offer trigger.